S&P Biotech ETF (CURE) – Global X ETFs Australia
Australia
Search

CURE

S&P Biotech ETF

Invest in CURE Request Research
Overview Performance Holdings & Characteristics Research Documents Announcements FAQs

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 1 Jul 2024

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 1 Jul 2024

NAV/Unit (A$) 47.78000000
Currency (NAV) AUD
Shares Outstanding 824,012
AUM (A$) 39,371,281.96
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 31 May 2024

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 1 Jul 2024

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month 4.57% 4.61% -0.04% 0.64%
3 Months -4.02% -3.91% -0.11% 0.74%
1 Year 11.61% 12.37% -0.76% 0.82%
3 Year p.a. -9.02% -8.74% -0.28% 1.07%
5 Year p.a. 1.73% 2.14% -0.41% 0.90%
10 Year p.a. -- -- -- --
Since Inception p.a. 3.19% 3.61% -0.42% 0.87%

Top Holdings As of 2 Jul 2024

Full Holdings (.xlsx)
Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
3.28 SAREPTA THERAPEU B8DPDT7 156.75 5,483 1,292,324
2.98 UNITED THERAPEUT 2430412 319.01 2,446 1,173,293
2.86 ALNYLAM PHARMACE B00FWN1 243.32 3,083 1,127,969
2.84 GILEAD SCIENCES 2369174 68.64 10,830 1,117,767
2.80 AMGEN INC 2023607 311.01 2,359 1,103,184
2.75 REGENERON PHARM 2730190 1,057.02 680 1,080,781
2.73 EXACT SCIENCES 2719951 42.43 16,824 1,073,366
2.72 ABBVIE INC B92SR70 170.37 4,179 1,070,560
2.70 VIKING THERAPEUT BQQG1V1 55.32 12,756 1,061,066
2.69 BIOGEN INC 2455965 231.77 3,041 1,059,789
2.65 BIOMARIN PHARMAC 2437071 82.13 8,437 1,041,923
2.64 VERTEX PHARM 2931034 471.25 1,466 1,038,798
2.57 NATERA INC BYQRG48 107.81 6,245 1,012,365
2.50 INCYTE CORP 2471950 60.87 10,750 983,915
2.45 NEUROCRINE BIOSC 2623911 140.11 4,581 965,106
2.23 MODERNA INC BGSXTS3 115.95 5,032 877,318
2.08 CYTOKINETICS INC BBBSBJ5 54.70 9,968 819,863
1.51 BLUEPRINT MEDICI BWY52P3 109.18 3,610 592,647
1.48 MADRIGAL PHARMAC BD59BS7 279.31 1,384 581,257
1.43 CRISPR THERAPEUT BDHF4K6 53.95 6,939 562,904
1.30 ROIVANT SCIENCES BMW4NZ9 10.83 31,534 513,515
1.27 APELLIS PHARMACE BYTQ6X1 36.29 9,198 501,910
1.14 IONIS PHARMACEUT BDJ0LS6 47.11 6,357 450,309
1.13 EXELIXIS INC 2576941 22.25 13,279 444,264
1.10 CEREVEL THERAPEU BMVMJ12 41.35 6,967 433,179
1.10 KRYSTAL BIOTECH BD6JX35 182.27 1,574 431,386
1.08 INSMED INC 2614487 66.34 4,265 425,442
1.05 VAXCYTE INC BKPVGH6 76.94 3,565 412,437
1.04 REVOLUTION MEDIC BL71K91 38.81 6,989 407,854
1.01 ALKERMES PLC B3P6D26 24.39 10,861 398,316
0.99 BRIDGEBIO PHARMA BK1KWG8 25.20 10,324 391,196
0.99 BIOHAVEN LTD BPLZ7S5 35.31 7,366 391,089
0.98 HALOZYME THERAPE 2975098 52.02 4,931 385,701
0.88 TG THERAPEUTICS B828K63 18.15 12,686 346,216
0.86 SPRINGWORKS THER BGMGM89 38.53 5,869 340,023
0.78 IOVANCE BIOTHERA BF0DMK7 8.06 25,362 307,372
0.75 ULTRAGENYX PHARM BJ62Z18 41.12 4,750 293,692
0.74 CRINETICS PHARMA BDD19F8 46.07 4,223 292,540
0.74 DYNE THERAPEUTIC BN15WD1 35.49 5,473 292,063
0.73 TWIST BIOSCIENCE BGKG6G7 48.93 3,881 285,538
0.70 ACADIA PHARMACEU 2713317 16.04 11,486 277,025
0.70 NUVALENT INC-A BMVBZD3 75.51 2,436 276,584
0.70 ARDELYX INC BN89V40 7.57 24,197 275,425
0.67 INTELLIA THERAPE BYZM6C2 22.47 7,851 265,261
0.67 CELLDEX THERAPEU BJLV8T9 38.99 4,499 263,764
0.66 ARCELLX INC BPCJ1Q2 53.60 3,231 260,404
0.65 AVIDITY BIOSCIEN BMWHPY1 41.28 4,116 255,482
0.64 AMICUS THERAPEUT B19FQ48 9.80 17,193 253,351
0.64 VERA THERAPEUTIC BL55460 36.29 4,584 250,137
0.62 IDEAYA BIOSCIENC BK0VHF6 35.92 4,524 244,346
0.60 GERON CORP 2370381 4.34 36,423 237,690
0.56 IMMUNOVANT INC BJRFSB7 27.51 5,297 219,112
0.55 SYNDAX PHARMACEU BN7Q7R7 21.53 6,698 216,838
0.55 ARROWHEAD PHARMA BYQBFJ8 26.05 5,517 216,101
0.55 BEAM THERAPEUTIC BK6L288 23.05 6,222 215,649
0.50 DYNAVAX TECHNOLO BRJZSK0 11.16 11,735 196,921
0.48 DENALI THERAPEUT BD2B4V0 22.01 5,703 188,742
0.48 NOVAVAX INC BJDQXG4 12.73 9,859 188,715
0.48 AGIOS PHARMACEUT BCBVTX1 43.38 2,893 188,705
0.46 ADMA BIOLOGICS I B9NSBM2 11.55 10,537 182,997
0.46 JANUX THERAPEUTI BMFX8Y7 41.72 2,908 182,425
0.45 PTC THERAPEUTICS B17VCN9 31.17 3,782 177,257
0.45 BIOCRYST PHARM 2100362 6.67 17,534 175,854
0.45 RHYTHM PHARMACEU BF2YWG4 42.67 2,732 175,287
0.43 VERICEL CORP BSBMN89 45.03 2,489 168,528
0.43 RECURSION PHAR-A BM9FJ13 7.46 14,980 168,034
0.42 CATALYST PHARMAC B1G7Q03 15.77 6,984 165,608
0.42 APOGEE THERAPEUT BM9HHL5 38.58 2,818 163,474
0.41 NURIX THERAPEUTI BMVLGP2 20.91 5,170 162,551
0.40 KYMERA THERAPEUT BMPRZV5 30.95 3,419 159,113
0.40 AKERO THERAPEUTI BK7Y2V9 23.16 4,556 158,660
0.39 IMMUNITYBIO INC BNSP0B8 6.27 16,402 154,636
0.38 PROTAGONIST THER BDCBCD8 35.20 2,834 149,999
0.38 KURA ONCOLOGY IN BYZD465 21.20 4,690 149,505
0.36 KEROS THERAPEUTI BM7V485 43.77 2,167 142,620
0.36 IRONWOOD PHARMAC B3MZ6K5 6.52 14,470 141,861
0.36 ARCUTIS BIOTHERA BKX9VD3 9.56 9,769 140,428
0.35 ROCKET PHARMACEU BDFKQ07 20.66 4,429 137,588
0.35 MORPHIC HOLDING BK8M4J4 32.55 2,807 137,385
0.34 MIRUM PHARMACEUT BJDX8Y8 34.16 2,592 133,137
0.34 VERACYTE INC BFTWZY0 21.33 4,145 132,942
0.33 SOLENO THERAPEUT BL6JK96 42.29 2,031 129,150
0.32 MYRIAD GENETICS 2614153 23.97 3,519 126,833
0.29 4D MOLECULAR THE BKLXFX5 21.34 3,598 115,452
0.29 DAY ONE BIOPHARM BLB0YH0 13.58 5,634 115,044
0.29 PROTHENA CORP PL B91XRN2 20.48 3,653 112,493
0.28 VIRIDIAN THERAPE BMDH2B6 13.21 5,458 108,413
0.27 SANA BIOTECHNOLO BMFJJ97 5.47 12,817 105,419
0.27 ARCTURUS THERAPE BKC9SX3 23.66 2,937 104,488
0.26 XENCOR INC BGCYWN8 19.02 3,596 102,843
0.26 MANNKIND CORP BF081J4 5.09 13,191 100,958
0.25 CULLINAN THERAPE BM90J52 16.73 3,940 99,115
0.24 PRAXIS PRECISION BQ721R4 41.19 1,557 96,433
0.24 SPYRE THERAPEUTI BQBBDY8 24.55 2,526 93,246
0.24 COGENT BIOSCIENC BLR6XK8 8.94 6,926 93,103
0.23 CG ONCOLOGY INC BRBCSP4 31.72 1,919 91,528
0.23 ALTIMMUNE INC BFY7DC4 7.20 8,343 90,323
0.22 TRAVERE THERAPEU BLFGJD5 8.28 6,863 85,446
0.21 ARCUS BIOSCIENCE BDZT9Y9 15.30 3,606 82,959
0.20 IMMUNOME INC BM8FWX7 12.20 4,369 80,147
0.20 CAREDX INC BP3YM74 15.38 3,367 77,866
0.20 SAGE THERAPEUTIC BP4GNK9 11.03 4,640 76,955
0.19 SUMMIT THERAPEUT BMTVQS7 8.14 6,246 76,449
0.19 VIR BIOTECHNOLOG BK4PZ38 9.10 5,491 75,134
0.19 AVID BIOSERVICES BFMZ4W7 7.12 6,939 74,289
0.19 OCUGEN INC BK71M09 1.63 30,011 73,330
0.18 RELAY THERAPEUTI BN2R582 6.40 7,301 70,260
0.18 ANAPTYSBIO INC BDRW1L7 24.61 1,870 69,199
0.16 CORBUS PHARMACEU BNHTR76 49.40 874 64,921
0.16 REGENXBIO INC BZ0G875 11.07 3,885 64,667
0.16 OLEMA PHARMACEUT BMZ4LN0 11.14 3,840 64,322
0.16 DISC MEDICINE IN BMGJZJ8 46.47 903 63,097
0.16 89BIO INC BK1K484 7.76 5,404 63,055
0.16 STOKE THERAPEUTI BJQ05Z6 13.87 3,008 62,734
0.16 SCILEX HOLDING C BLKFRT9 1.88 21,910 61,936
0.16 KINIKSA PHARMACE BRXB0C0 18.00 2,282 61,764
0.16 SCHOLAR ROCK HOL BFZQ0L8 8.13 5,007 61,209
0.15 ASTRIA THERAPEUT BMYRFN8 9.25 4,135 57,513
0.14 EDITAS MEDICINE BZ8FPH3 4.61 8,090 56,078
0.14 ALLOGENE THERAPE BFZNYB7 2.33 15,704 55,019
0.13 MIMEDX GROUP INC B1Z3TW5 6.70 5,202 52,407
0.13 ANAVEX LIFE SCIE BYTYP72 4.11 8,445 52,190
0.13 C4 THERAPEUTICS BKX9NQ0 4.85 6,993 50,998
0.13 HERON THERAPEUTI BJ0XLZ3 3.47 9,697 50,596
0.13 ORIC PHARMACEUTI BKVDFF7 7.64 4,375 50,259
0.12 FATE THERAPEUTIC BCZS820 3.26 9,442 46,284
0.12 CABALETTA BIO IN BK5MWR1 7.81 3,900 45,800
0.11 ARS PHARMACEUTIC BMCR7V2 8.73 3,212 42,163
0.11 VERVE THERAPEUTI BNKGXX2 4.98 5,619 42,076
0.10 ZENTALIS PHARMAC BMQ5T49 4.19 6,309 39,748
0.10 VOYAGER THERAPEU BY7RB53 7.86 3,360 39,711
0.09 TANGO THERAPEUTI BP2P6L0 9.00 2,744 37,134
0.09 CARGO THERAPEUTI BQHN2F2 16.00 1,523 36,641
0.09 SAVARA INC BYXGN81 4.64 5,107 35,631
0.08 HUMACYTE INC BMYTJP4 5.37 3,927 31,709
0.08 ITEOS THERAPEUTI BMWXFT4 15.01 1,355 30,582
0.06 ALECTOR INC BJ4LDC4 4.42 3,789 25,182
Holdings are subject to change.

Sector Breakdown As of 2 Jul 2024

Sector Weight (%)
Health Care 99.9
Other/Cash 0.1

Country Breakdown As of 2 Jul 2024

Country Weight (%)
United States 97.1
Switzerland 1.4
Ireland 1.3
Other/Cash 0.2

Research

Investing in Pharma: The Drug Lifecycle

Read More

Charting Disruption: Medical Breakthroughs

Read More

AI Applications in Healthcare: From Drug Discovery to Patient Care

Read More

Documents

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.

  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.

  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.

  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.

  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top